Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Theratechnologies Highlights Trogarzo Data At AIDS 2022; Co Says Data Shows Potential for Improved Treatment Regimens

New sub-analysis on Trogarzo clinical trial patients demonstrates that long-term viral suppression is not influenced by partially active agents. Predictive pharmacokinetic modelling shows that new methods of
byBenzinga Newsdesk
July 28, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • New sub-analysis on Trogarzo clinical trial patients demonstrates that long-term viral suppression is not influenced by partially active agents.
  • Predictive pharmacokinetic modelling shows that new methods of administration could provide similar kinetics to intravenous infusion.
    • Additional data highlights synergistic activities between Trogarzo and dolutegravir, etravirine, tenofovir alafenamide and lenacapavir, a long-acting investigational antiretroviral therapy (ARV).
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts